Multiple myeloma clinical trials are both a treatment option for all types of patients and the core way that new advances are made in myeloma care.
Learn more in this Myeloma Clinical Trials section to learn about:
- Different phases of clinical trials (Phase I, II and III)
- Myeloma drugs or therapies currently in clinical trials
- Clinical trial considerations for myeloma patients
To find a myeloma-specific clinical trial that you are personally eligible to join, click here.
This clinical trial aims to find out whether glutamine metabolism in plasma cells is necessary and if it affects the progression of MGUS.
Leflunomide is an immunomodulatory and immunosuppressive drug that is used to treat autoimmune diseases. New data suggests we can start using it for myeloma.
A clinical trial related to Teclisimab aiming to help patients with High-Risk Smoldering Myeloma (HRSM).
Emory University has an open study using iberdomide to treat smoldering myeloma patients.
Your myeloma story can accelerate myeloma research.
A study looking to find markers that can predict why some patients develop multiple myeloma while others do not.
Learn more about Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma patients.
Isatuximab is testing IV administration compared to a new on-body delivery system in multiple myeloma
A new BCMA CAR T for relapsed/refractory myeloma called zevor-cel is in a phase I/II clinical trial